– USA, CA – Progenity, Inc., a privately-held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced the appointment of Brian Kotzin, M.D., to its board of directors.
Dr. Kotzin’s experience in the development of novel biotherapeutics, especially in autoimmune and inflammatory diseases, will provide valuable guidance as the company advances its pipeline of precision therapeutics/biotherapeutics and diagnostics.
“We’ve made significant strides to address enduring challenges in the diagnosis and treatment of gastrointestinal diseases. To support these advances, we add another outstanding industry leader to our board – Dr. Kotzin,” said Harry Stylli, Ph.D., CEO, Chairman of the Board, and co-founder of Progenity. “His familiarity and expertise with development strategies from biomarker discovery through late-stage clinical development will be beneficial as we advance our diagnostic and therapeutic platforms towards the clinic and to commercial use.”
About Dr Brian Kotzin
Dr. Kotzin brings experience including more than 25 years of academic research and 15 years of executive leadership for life science companies. Dr. Kotzin is a Board of Directors member at Rigel, currently serves as a Principal Fellow and Senior Vice President for Nektar Therapeutics and consults for companies developing therapeutics for autoimmune and inflammatory diseases. His previous roles include Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area and Vice President and Head of Medical Sciences at Amgen. Prior to entering the life sciences industry, he held several positions as a professor at the University of Colorado Health Sciences Center, where his research focused on the immunopathogenesis of the disease. He received a doctorate in medicine from Stanford University and a bachelor’s degree in mathematics from the University of Southern California.
“Advancements in precision medicine technologies hold substantial promise to improve patient care and allow scientists to better understand disease progression,” said Dr. Kotzin. “I am excited to offer my knowledge and experience across basic research and clinical studies to help Progenity as it develops new products designed to advance the diagnostic and therapeutic landscape, ultimately leading to more accurate patient assessment and more impactful treatment.”
Dr. Kotzin has held leadership roles at several national organizations, including as a member of the American College of Rheumatology Board of Directors, Member and Chairperson of the NIH Immunological Sciences Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for the Federation of Clinical Immunology Societies. He is currently an elected Master of the ACR.
Progenity, Inc. is a privately held biotechnology company with the mission of transforming healthcare to be more precise and personal. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics/epigenomics, proteomics, and microbiomics. These platforms feed an R&D pipeline of innovative products designed to improve patient outcomes in prenatal and perinatal healthcare settings, oncology, and gastroenterology. Progenity’s ultimate vision is to make precision medicine a reality by both diagnosing diseases at its source and treating it with targeted therapies developed by the company. Progenity is headquartered in San Diego, California.
For more information: https://www.progenity.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.